SuperworthVertex Pharmaceuticals VRTX
- Market cap
- $132.8B
- PE
- 30.5×
- 9y median 28.6×
- Forward PE
- 27.0×
- 10y median 26.4×
- Price to sales
- 10.6×
- EV/EBIT
- 26.6×
- Revenue, 12 months
- $12.6B
- +10% on a year ago
- Net margin
- 35.0%
- Free cash flow yield
- 2.9%
Vertex Pharmaceuticals trades at 30.5× trailing earnings, near its ten-year median. Revenue was $12.6B over the last twelve months, up 10% on a year earlier with a 35% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.5B+6% | $2.5B+9% | $2.7B+13% | $2.6B+6% | $2.8B+12% | $2.9B+16% | $2.8B+3% | $3B+12% | $3.1B+11% | $3.2B+10% | $3B+8% | $3.3B+13% | |
| Cost of revenue | $318.7M+10% | $368M+30% | $342.6M+28% | $371.9M+21% | $392.6M+23% | $423.4M+15% | $363M+6% | $407.5M+10% | $414.8M+6% | $466M+10% | $392.8M+8% | $489.2M+20% |
| Gross profit | $2.2B+6% | $2.1B+7% | $2.3B+11% | $2.3B+4% | $2.4B+10% | $2.5B+16% | $2.4B+3% | $2.6B+13% | $2.7B+12% | $2.7B+10% | $2.6B+8% | $2.8B+11% |
| R&D | $810M+26% | $824.6M+19% | $789.1M+6% | $966.6M+23% | $875.9M+8% | $998.7M+21% | $979.7M+24% | $978.4M+1% | $977.7M+12% | $973.7M−3% | $961.6M−2% | $993.8M+2% |
| SG&A | $263.8M+7% | $369.1M+38% | $342.7M+42% | $372.2M+42% | $371.8M+41% | $377.6M+2% | $396.4M+16% | $424.6M+14% | $445.1M+20% | $487M+29% | $493.7M+25% | $582.2M+37% |
| $1B−8% | $988.5M−4% | $1.1B+46% | −$3.5B | $1.1B+8% | $1B+4% | $630.1M−45% | $1.2B | $1.2B+6% | $1.2B+18% | $1.1B+81% | $1.2B+8% | |
| Interest expense | $10.9M−20% | $10.6M−9% | $10.4M−9% | $9.9M−12% | $7.5M−31% | $2.8M−74% | $3M−71% | $3.7M−63% | $3.3M−56% | $3.3M+18% | n/a | n/a |
| Pre-tax income | $1.2B+0% | $1.1B+7% | $1.3B+44% | −$3.4B | $1.2B+4% | $1.1B−1% | $730.4M−43% | $1.3B | $1.3B+6% | $1.3B+17% | $1.3B+72% | $1.4B+9% |
| $143.9M−42% | $178.8M−31% | $179.5M−6% | $202.4M−18% | $178.7M+24% | $223.5M+25% | $84.1M−53% | $250.1M+24% | $215.9M+21% | $139.9M−37% | $221.5M+163% | $292M+17% | |
| Net income | $1B+11% | $968.8M+18% | $1.1B+57% | −$3.6B | $1B+1% | $913M−6% | $646.3M−41% | $1B | $1.1B+4% | $1.2B+31% | $1B+60% | $1.1B+7% |
| $3.97+11% | $3.71+18% | $4.21+57% | −$13.92 | $4.01+1% | $3.50−6% | $2.49−41% | $3.99 | $4.20+5% | $4.65+33% | $4.02+61% | $4.31+8% | |
| 260.6M+0% | 260.9M+0% | 261.1M+0% | 258.1M−1% | 261M+0% | 260.5M−0% | 259.5M−1% | 258.9M+0% | 257.6M−1% | 256.1M−2% | 256.3M−1% | 255.2M−1% |
Gross profit: 63 periods, Q2 FY10 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY14 and Q4 FY15: quarter's net income to common over its shares, to the cent. 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: Q4 FY14 and Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $3.4B | $3.4B to $3.5B | $4.80 | $4.26 to $5.12 | 10 |
| Q4 FY26 | $3.5B | $3.5B to $3.6B | $4.72 | $4.11 to $5.31 | 10 |
| Q1 FY27 | $3.4B | $3.3B to $3.5B | $4.77 | $4.67 to $4.92 | 8 |
| Q2 FY27 | $3.6B | $3.5B to $3.7B | $5.08 | $4.98 to $5.25 | 8 |
| Q3 FY27 | $3.7B | $3.7B to $3.8B | $5.31 | $5.21 to $5.49 | 8 |
| Q4 FY27 | $3.9B | $3.8B to $4B | $5.67 | $5.55 to $5.85 | 8 |
| Q1 FY28 | $3.5B | $3.4B to $3.6B | $0.00 | 9 | |
| Q2 FY28 | $3.6B | $3.5B to $3.7B | $0.00 | 9 |
Peers
Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals | $132.8B | 30.5× | 28.6× | 27.0× | 10.6× | +10% | 35.0% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| Peer median | $24.3B | 21.0× | 29.8× | 26.7× | 6.4× | +31% | 26.3% |
Investors who own it
Investors we follow who held Vertex Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.1% of portfolioadded
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Vertex Pharmaceuticals
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 29Biotech stocks with the highest profit margins
- #9of 16Biotech stocks with the lowest PE ratio
- #9of 14Biotech stocks with the fastest earnings growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .